Assessment of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information in Korea.

Trial Profile

Assessment of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information in Korea.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs GSK 2321138A (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Mar 2017 Planned End Date changed from 1 Mar 2020 to 1 Jun 2020.
    • 03 Mar 2017 Status changed from not yet recruiting to active, no longer recruiting.
    • 04 Oct 2016 Planned End Date changed from 1 Dec 2021 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top